Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGDS | O60760 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.41 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7229196 | 0.79 | NPC1 (0.61) | NPC1RAB9APOLBMAOBLMNA | |
| SCHEMBL14616443 | 0.76 | NPC1 (0.44) | NPC1RAB9APOLBMAOBLMNA | |
| SCHEMBL2566342 | 0.75 | ALDH1A1 (0.48) | POLBHPGDSLMNASMN1; SMN2KMT2A | |
| SCHEMBL31341053 | 0.74 | CDK5 (0.48) | NPC1RAB9APOLBLMNASMN1; SMN2 | |
| SCHEMBL4141440 | 0.73 | NPC1 (0.50) | NPC1RAB9APOLBMAOBSMN1; SMN2 | |
| SCHEMBL16941896 | 0.72 | NPC1 (0.52) | NPC1RAB9APOLBMAOBLMNA | |
| SCHEMBL29777588 | 0.72 | POLB (0.61) | NPC1RAB9APOLBLMNASMN1; SMN2 | |
| SCHEMBL12287412 | 0.72 | L3MBTL1 (0.43) | NPC1RAB9APOLBMAOBLMNA | |
| SCHEMBL18640773 | 0.72 | POLB (0.65) | NPC1RAB9APOLBMAOBLMNA | |
| SCHEMBL8789037 | 0.71 | HDAC1 (0.62) | NPC1RAB9APOLBLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758059-B1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME (US) | 2018-10-24 | — | — | EP | disclosed |
| EP-2560655-B1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME (US) | 2016-08-24 | — | — | EP | disclosed |
| EP-2560655-B1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME (US) | 2016-08-24 | — | — | EP | disclosed |
| US-9079930-B2 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079930-B2 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079930-B2 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9006433-B2 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006433-B2 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006433-B2 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140349972-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP (US) | 2014-11-27 | — | — | US | disclosed |
| WO-2013040790-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013040790-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
| EP-2560655-A1 | SUBSTITUTED PYRIMIDINES | Merck Sharp & Dohme Corp. (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20130018053-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME LLC | 2013-01-17 | — | — | US | disclosed |
| US-20130018053-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME LLC | 2013-01-17 | — | — | US | disclosed |
| US-20130018053-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME LLC | 2013-01-17 | — | — | US | disclosed |
| WO-2011133444-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133444-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011130908-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011130908-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018053-A1 | SUBSTITUTED PYRIMIDINES | HIF1AN, HIF1A, EGLN3 | NPC1 3276/4885RAB9A 4227/4885POLB 324/4885 |
| US-20140349972-A1 | SUBSTITUTED PYRIMIDINES | HIF1AN, HIF1A, EGLN3 | NPC1 3276/4885RAB9A 4227/4885POLB 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.